


SUPPLEMENTAL INFORMATIONS

Figure S1 Cumulative ZIKV production by testis explants over a 9 day-culture period. Viral titer values presented in Figure 1B (viral release over a 3 day-culture period measured at day 3, day 6 and day 9 p.i.) were summed to obtain cumulative TCID₅₀ units production over the 9 day-culture period for each testis explants of the eight donors. Dotted line represents the TCID₅₀ input used for infection.




Figure S2 Replication of ZIKV H/PF/2013 in human testicular tissue. Human testis explants from 6 donors were ex vivo-infected overnight with 10^5 TCID₅₀ (corresponding to 8.10^7 vRNA copies) of a low-passage Asian ZIKV strain isolated in 2013 in French Polynesia (H/PF/2013). Explants were thoroughly washed and then cultured on inserts in 1 ml of medium/well for 9 days, with media fully removed and changed every 3 days. Each of the time points (day 3, day 6, day 9) represents de novo viral release over a 3-day-culture period. A) ZIKV RNA release over a 3-day-culture period at day 3, day 6 and day 9 detected by RT-qPCR; B) Viral titers determined by infectivity assay of 3-day-culture period tissue supernatants on VeroE6 cells. Each symbol represents a different donor (same symbol/donor throughout the manuscript figures). Dotted lines represent the detection limit of the assays. Mock-infected explants were always below detection level. Bars represent median. *P<0,05 (Friedman-Dunns non-parametric comparison).




Figure S3 RNAscope in situ hybridization (ISH) set-up. Paraffin-embedded cell pellets (A-E) and testis tissue (F-G) underwent ISH using different probes (indicated in red). A) Vero E6 cells infected with ZIKV for 1 day showing specific punctuate red dot staining; B) Vero E6 cells infected with ZIKV for 3 days, showing intense clusters of red dots covering the cells, reflecting high infection level; C) mock-infected Vero E6; D-E) HeLa cells; F-G) Testicular tissue sections. A-C) VeroE6 cells were stained for ZIKV RNA for positive (A,B) and negative (C) controls of ISH; D, F) ISH positive control using a probe targeting human polr2a gene; E, G) ISH negative control using a probe targeting bacterial gene dapB. Scale bars=100 μ m.




Figure S4 Localization of ZIKV infected cells in testicular explants at different time points of infection. RNAscope in situ hybridization for ZIKV RNA coupled to immunofluorescence for α SMA (which labels peritubular cells, thus delineating seminiferous tubules, and smooth muscle cells in blood vessels walls) in mock-infected (A) and day-3 (B), day-6 (C), day-9 (D) ZIKV-infected testis explants. Nuclei are stained in blue. Scale bars=100 μ m.




Figure S5 ZIKV infection of testicular germ cells T-cam2. The human testicular germ cell line Tcam-2 was infected for 2h with ZIKV (MOI 1, corresponding to 1.43×10^5 TCID₅₀ units/ml/0.1 million cells). Viral inoculum was washed away and cells trypsinized to remove residual virus. Incubated media and cells were collected at the indicated time points post-infection. ZIKV RNA detected by RT-qPCR in cells (A) and culture supernatants (B). Mean+/- SEM of 3 independent experiments is represented. C) Immunofluorescence against ZIKV envelope (ZIKV-E) protein. Nuclei are stained in blue. Scale bars=20 μ m. D) Viral titers determined by infectivity assay of tissue supernatants on VeroE6 cells. Each dot represents a different experiment. Bars represent median values. Dotted lines indicate detection limits.




Figure S6 Detection of ZIKV in spermatozoa. Semen smear obtained from an infected donor 11 days post-symptoms onset stained with anti-ZIKV-E antibody. Nuclei are stained in blue. Merged with brightfield image to visualize cell's morphology. Scale bars=20 μ m.




Figure S7 Testicular gene expression in infected versus mock-infected testis explants. Mock-infected and ZIKV-infected testis explants from 6 donors were collected at day 3, 6 and 9 post-infection and assessed by RT-qPCR for relative expression of A) steroidogenic enzymes mRNAs and B) specific transcripts for Sertoli cells (Inhibin B), peritubular myoid cells (Acta2), early meiotic (PGK2) and post-meiotic (PRM2) germ cells. Graphs represent mean +/- SEM for 6 testis donors. Dotted lines show basal expression levels in mock-infected explants.




Figure S8 Cytokines secretion in ZIKV-infected and mock-infected testis explants. Levels of cytokines in supernatants of testis explants from 7 donors were measured by flow-cytometer based multiplex assay (Legendplex). TNF α and IL-12p70 concentration levels are not shown as they were below the detection threshold. Dotted lines indicate quantification limits. Each symbol represents a different donor. Bars represent median values.




Figure S9 Gene expression correlations in infected human testis. Heatmap of Spearman correlation of day 9 gene expression fold increase with viral loads in supernatants at days 3, 6 and 9 post-infection (d3, d6, d9 p.i.) (left panel) or between each pair of upregulated (right panel) genes from 6 testis explants donors (T1 to T6). Cells with a Spearman rho value higher than 0.75 and 0.9 are indicated with light and dark green respectively. Rho values are reported in cells when correlation is statistically significant ($p < 0.05$, regular font; $p < 0.01$ bold underlined).




Figure S10 ZIKV triggering of gene expression at early time points post-infection. To investigate the expression before day 3 post-infection of IFN and other genes involved in pathogen sensing, antiviral response, inflammation, chemoattraction and immunotolerance, RT-qPCR was performed on testis explants from two donors (T7 and T8) exposed to 10^5 TCID₅₀ of ZIKV for 18h and 48h. Testis explants from one donor (T8) were also collected at 4h post-infection. As a control for the ability of ZIKV to induce gene expression in these testis donors, infected explants were screened in RT-qPCR at day 9 post-infection. Heat map shows log2 transformed expression ratios between ZIKV infected and time-matched mock-infected controls. On the scale bar, green indicates up-regulation and red, down-regulation compared to mock-infected controls Type I ($\alpha 1, \alpha 2, \alpha 4, \beta, \lambda 2, \lambda 3$) and II (γ) IFN mRNAs were below quantification threshold (not shown).




Figure S11 Immune cells infiltrates in ZIKV-infected mouse testis. (A) Detection of T lymphocytes in mock-infected and ZIKV-infected mouse testis at day 5 and day 9 post-infection by immunofluorescence with anti-CD3 antibody. Nuclei are stained in blue. Scale bars=100μm. (B) Quantification of CD3+ cells in mock-infected, day 5 infected and day 9 infected mouse testis. Each symbol represent a different animal. * P<0,05 (Kruskal–Wallis-Dunn's test non-parametric comparison).

Supplementary Table 1. Primers used for the relative quantification of innate immune response effector genes

Human genes

Gene	Forward primer (5'-3')	Reverse primer (5'-3')
ACTb	TACAGCTTCAACCACCGA	TGCTCGAAGTCAGGGCGA
CCL2	AGCAGCAAGTGTCCAAAGAAG	AGTCTTCGGAGTTGGGTTGC
CCL5	TGCTGCTTGCCCTACATTGCC	TTTCGGGTGACAAAGACGACTG
CCR7	AGTGGGGAGACTTCTTGGCTG	AAAACGATGGAGGGAGGGGTTTC
CD14	GTAATCCCCTCAAGGAACG	AAAGTGCAAGTCCTGTGGCTTC
CD163	TGAGCCACACTGAAAAGGAAAATG	GCTCCATTCAATAGTCCAGGTCTTC
CD64a	ACACATCAGCAGGAATATCTGTCAC	GAGCAACTTGTTCACAGCTCAGG
CXCL1	TTCACAGTGTGTTCAACATTTC	CCCTTTGTTCTAACGCCAGAACAC
CXCL10	GTGGCATTCAAGGAGTACCTCTC	CGTGGACAAAATTGGCTTCAG
CXCI2	CACAGTGTGTTCAACATTCTC	TGCTCTAACACAGAGGGAAACAC
HLADR	CCTTGACCTCAGTGAAAGCAGTC	AGAGTACGGAGCAATCGAAGAGG
IFI27	AGTCACTGGGAGCAACTGGAC	CTGGCATGGTTCTCTCTGC
IFIT1	CTTGAGCCTCCTGGGTTCTC	GTTCTCAAAGTCAGCAGCCAGTC
IFITM1	CCGTGAAGTCTAGGGACAGGAAG	CACAGAGCCGAATACCAAGTAACAG
IFNa1	ACCCACAGCCTGGATAACAG	TCCATCAGACAGGGAGGAAGG
IFNa2	AAACTGGTTCAACATGGAAATGATT	CATGAGTCTTGAAATGGCAGATC
IFNa4	CCGTGCTGGTGCTCAGCTA	GCTGTGGGCTGAGGCAGAT
IFNb	CAGAACGCTCTGGCAATTG	TCCTCAGGGATGTCAAAGTTCA
IFNL1	GAATTGGGACCTGAGGCTCTC	GATGTGGTCAGGGTGTGAAGG
IFNL2,3	CTGCCACATAGCCCAGTTCAAG	CGACTCTCTAACGGCATCTTGGC
IL10	GCTGGAGGACTTTAAGGTTACCTG	GGGTCTGGTTCTCAGCTGGG
IL1b	CACGATGCACCTGTACGATCAC	ACATGGAGAACACCAACTCGTTGC
IL6	TGTTTCTGCCAGTGCCTCTT	ACACAGACAGCCACTCACCTC
IRF7	CGCTATACCATCTACCTGGGCTTC	GCTGCTATCCAGGGAAAGACACAC
ISG15	CGAACCTCTGAGCATCCTGGTG	CCTCGAAGGTCAGCCAGAACAG
MCSF	GATGGAGACCTCGTGCCAAATTAC	TATCTCTGAAGCGCATGGTGTCC
MDA5	AAAGCACTGAAAAGAAGTGTGC	TGCACCATCATTGTTCCCCAAG
MX1	CGTTAGCCGTGGTAGTTAGCAG	ATCCTTCAATCCGCCAGCTC
MX2	CCAGTAATGAGTCTCGGTTCTC	GAGACGTTGCTGGTTCCAAGAAG
OAS1	GATGTGCTGCCTGCCCTTGATG	TCGATGAGCTTGACATAGATTGGG
OAS2	CTGAGCCAGTTGCAGAAAACCAG	CAGAAGATGCCAACACCAACGG
RSAD2	ACATGACGGAACAGATCAAAGCAC	AGCATCTTCTCCACAATTCTCACC
RIG1	GACACAGAGAGTCTGGCAAAGAG	CTTTGTCTGGCATCTGGAACACC
SOCS1	GCAGACCCCTCTCACCTCTG	GAGGTAGGAGGTGCGAGTTAG
SOCS3	TAAGGGTAAAGGGCGCAAAGG	CCTGGTTGGCTCTGTGCTTG
TGFb	TCCTGGCGATACCTCAGCAAC	GGCGAAAGCCCTCAATTCCC
TNFa	CTGTAGCCCATGTTAGCAAACC	TCTCTAGCTCCACGCCATTG

Mouse genes

Gene	Forward primer (5'-3')	Reverse primer (5'-3')
ACTb	TGGATCAGCAAGCAGGAGTACG	AAAACGCAGCTCAGTAACAGTCC
CD14	GACCATGGAGCGTGTGCTTG	TTGAAAGCGCTGGACCAATCTG
CD19	CCGAGGAAACCTGACCATCGAG	ACTGGGACTATCCATCCACAG
CD20	TTCAAACCCAAGCCGTATGTTG	AGAAGGCAGAGATCAGCATCGC
CD3E	CTGTATCACTCTGGGCTTGCTG	GCTCCTGTTTGCCTCTGG
CD3G	TATCTCATTGCCGGACAGGGATGG	CTGGTCATATTCCCGGTCTTG
CD4	TCTGACTCTGGACAAAGGGACAC	GGGTCAGTCTCATCTTGGGAGAG
CD68	CTTCGGGCCATGTTCTCTGC	AGAGGGGCTGGTAGGTTGATTG
CD8a	TGGCCCTCTGCTGTCCTG	ACTAGCGGCCTGGGACATTG
CD8b	TCAAGACGGCCCTTCTCAGTATC	TTGTTAGGAAGGACATCAACCACAG
CXCL10	GTCTGAGTCCTCGCTCAAGTGG	TAGGGAGGACAAGGAGGGTGTG
FOXP3	AGTCCTCCCCAGAGTCTTCCAC	AAGGGTGGCATAGGTGAAAGGG
IFIT1	GGCATCACCTCCTCTGGCTAC	TTTCGGGATGTCCTCAGTTGGG
IFITM1	AGCCTATGCCACTCCGTGAAG	CAGACAACGATGACGACGATGG
IFNa1	ATTCCCCTGACCCAGGAAGATG	AGGAAGACAGGGCTCTCAGAC
IFNa2	TCCTCGTGTGCTGATAGTGATGAG	CCTTCAGGCAGGAGAGAAAGGG
IFNa4	TGTCGCTACTTGAATGCAACTC	AGAGGAGGTTCTGCATCACAC
IFNb1	GATGAACTCCACCAGCAGACAG	GACATCTCCCACGTCAATCTTCC
IFNg	GGAGGAACTGGCAAAAGGATGG	TGTTGCTGATGGCCTGATTGTC
IFNL2,3	AGGATTGCCACATTGCTCAGTTC	AGCAGCCTTCTCGATGGC
IL1b	AAAGCTCTCCACCTCAATGGAC	TTGTCGTTGCTTGGTTCTCCTG
IL6	TTCCTACCCAATTCCAATGCTC	TTGGATGGTCTTGGTCCTTAGCC
ISG15	GGAACAAGTCCACGAAGACCAG	CTGGGGCTTAGGCCATACTCC
MDA5	ACATGAAACCAAGAGGAGTATGCAC	TGGATTGTCGTTGATTGCTTGC
MX1	CTTCCTGGTCGCTGTGCAATG	TACAAAGGGCTTGCTTGCCTCC
OAS1b	TGCTGAAGGAGGTGAAGTTGATG	TGGCGTAGAATTGTTGGTAGGC
RSAD2	GTGGTGCAGGGATTACAAGGTG	TTAGGAGGCACTGGAAAACCTTC
RIG1	GCAGAACAAACCGGGCAACAG	GTTATCTCCGCTGGCTCTGAATG
TNFa	GTAGCCCACGTCGTAGCAAAC	TCTTGAGATCCATGCCGTTGG